The study, published in the Journal of Clinical Oncology concluded that the failure rate was low with observation but was decreased significantly with the addition of radiotherapy.
Two-group randomized controlled trials often have a winner and a loser. But sometimes the results are "win—win." This appears to be the case with the first-ever randomized trial that compares adjuvant radiotherapy (RT) with observation in women with "good-risk" ductal carcinoma in situ (DCIS).
The investigators, led by Beryl McCormick, MD, from the Memorial Sloan Kettering Cancer Center in New York City, expect that their data will be used to endorse both treatment choices in the setting of good (or low-risk) DCIS. They say the trial results both "support" the decision to omit RT and "confirm" that RT offers "significant benefit in further reducing in-breast recurrence."
The study was published online January 20 in the Journal of Clinical Oncology.
Read the report on Medscape: http://bit.ly/1u3lu0U